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Introduction
Acute myeloid leukemia (AML) is an aggressive and heterogeneous cancer. 1, 2 Acute promyelocytic leukemia (APL) 3 , one of the variants of AML , has a favorable prognosis with up to 95% of patients achieving complete remission (CR), and about 75% are cured by the combination of all-trans retinoic acid (ATRA) treatment and chemotherapy. 4 Conversely, only 40-50% of patients with the non-APL variants achieve long-term AML-free survival after intensive chemotherapy often combined with allogeneic stem cell transplantation. [5] [6] [7] Although the CR rate is 60-85% for younger patients (18-60 years old) who can achieve the most intensive treatment 8 , many patients achieving CR after the induction therapy die from later chemoresistant relapse. 9, [10] [11] [12] [13] [14] Design of better treatments that avert AML relapse is therefore of great importance.
Genetic aberrations and mutations (e.g on CEBPA, NPM1 and TP53) are implemented in the diagnostic subclassification of AML patients and in risk adapted treatment procedures. [15] [16] [17] [18] [19] [20] However, liquid chromatography tandem mass spectrometry (LC-MS/MS)-based proteomics or phosphoproteomics can also be used for subclassification of patients with non-APL variants of AML. [21] [22] [23] [24] [25] [26] In the present study we therefore compared the proteome and phosphoproteome profiles of primary AML cells collected at the time of diagnosis for patients who later either became long-term leukemia-free survivors or suffered from chemoresistant relapse. Based on the proteomics and phosphoproteomics analysis of these two groups, we found common denominators in diagnostic samples which could be utilized for future treatments for patients that would later relapse.
Materials and methods

AML patients and sample collection
Written informed consent was obtained from all patients in accordance with the Declaration of Helsinki and the use of human leukemia cells for the present study was approved by the Regional Ethics Committee (REK III Vest 2013-634). Primary AML cells were collected from the peripheral blood of 41 patients with relatively high levels of circulating leukemia blasts at the time of diagnosis (i.e. >15 x 10 9 AML cells/L, >80% of circulating leukocytes). Highly enriched AML cell populations (>95%) could then be prepared by density gradient separation alone (Lymphoprep, Axis-Shield) 27 , and these enriched cells were then cryopreserved. 28 According to the patients' relapse status after 5-year clinical follow-up post diagnosis, we classified 15 patients as long-term survivors (i.e. REL_FREE patients) and 26 patients as chemoresistant relapse patients (i.e. RELAPSE patients) after achieving CR. See Figure 1A-B , Table 1 and   supplemental Table 1for a detailed description of these two groups. Nine AML patients external to the previously described cohort were used for validation studies and are described in detail in supplemental Table 2 . Karyotyping and analysis of mutations of 54 myeloid relevant genes were available for most patients (supplemental Methods).
AML super-SILAC mix
An AML spike-in reference was generated by combining Arg6-and Lys8-labeled protein cell lysates from five heterogeneous AML-derived cell lines, according to the super-SILAC (Stable Isotope Labeling with Amino acids in Cell culture) mix approach. 29, 30 The spike-in reference was added to each patient sample in an 1:2 ratio (w:w; super-SILAC mix:AML patient sample) for SILAC-based quantitation.
Patient sample preparation for proteomic and phosphoproteomic analysis
Sample preparation of patient cell lysate in 4% sodium dodecyl sulfate (SDS)/0.1 M Tris-HCl (pH 7.6) and immobilized metal affinity chromatography (IMAC) has been described earlier. 31 Briefly, 20 µg of each patient lysate was prepared both as 1) a label-free sample and 2) mixed with 10 µg of the super-SILAC mix for proteomic analyses, and processed according to the filteraided sample preparation (FASP) protocol 31, 32 (supplemental Methods; Figure 1C ). The super-SILAC spiked peptide samples were fractionated using styrenedivinylbenzene-reversed phase sulfonate (SDB-RPS) plugs (Empore, 3M). 33 The phosphoproteomics samples (64-1121 µg range) were mixed with the super-SILAC mix at the ratio described before, FASP processed and enriched for phosphopeptides using the IMAC procedure.
Nanoflow LC-MS/MS
Peptide sample preparation prior to LC-MS/MS and settings of the LC-MS/MS runs on a Q
Exactive HF Orbitrap mass spectrometer coupled to an Ultimate 3000 Rapid Separation LC system (Thermo Scientific) were conducted as described earlier for global proteomics samples 34 and phosphoproteomics 31 , and detailed in the supplemental Methods.
Data and bioinformatics analysis
LC-MS/MS raw files from RELAPSE and REL_FREE samples were processed with MaxQuant software version 1.5.2.8 35, 36 (supplemental Methods). The spectra were searched against the concatenated forward and reversed-decoy Swiss-Prot Homo sapiens database version 2018_02 using the Andromeda search engine. 37 The LC-MS/MS raw files and MaxQuant output files have been deposited to the ProteomeXchange consortium via the PRIDE partner repository 38, 39 with dataset identifier PXD014997 (Reviewer account details, username:
reviewer07592@ebi.ac.uk and password: jjAkVBC6). The Perseus 1.6.1.1 platform was used to analyze and visualize protein groups and phosphosites. 40 MaxQuant-normalized SILAC ratios were inverted, log 2 transformed and normalized again using width adjustment. Proteins and phosphosites (localization probability > 0.75) with at least five SILAC ratios in each patient group were selected for two-sample unequal variance t-test and Z-statistics 41 to find significantly different fold change (FC) for proteins and phosphosites between the RELAPSE and REL_FREE groups.
Hierarchical clustering of significantly differential proteins and phosphosites was done with Perseus using the Pearson correlation function and complete linkage. Gene ontology (GO) analysis of biological process, molecular function and cell compartment terms was performed using a GO tool. 42 The most significantly over-represented GO terms with false discovery rate (FDR) < .05 were displayed in bar plots in Prism8 (GraphPad Phosphosite and kinase prediction analyses were carried out as described in detail in supplemental Methods. Protein-protein interaction (PPI) networks were obtained by using the STRING database version 10.5 with interactions derived from experiments and databases at a high confidence score of 0.7. 44 Networks were visualized using the Cytoscape platform version 3.3.0. 45 The ClusterONE plugin was used to identify protein groups of high cohesiveness. 46
Enrichment analysis of transcription proteins binding sites
Putative binding sites of transcription proteins were found analyzing public available ChIP-seq data on K562 cell line at the ENCODE project. 47 ENCODE accession IDs of files are provided in supplemental Table 3 . Data analysis workflow was performed as detailed in supplemental
Methods.
Cell proliferation assay
The cytokine-dependent in vitro proliferation of enriched AML cells was analyzed by a 3Hthymidine incorporation assay (see supplemental Methods). 48 The median of triplicate determinations was used in all analyses. Mann-Whitney U test (SPSS Statistics version 25, IBM)
was employed for analysis of differences between different groups and Wilcoxon's matched-pair signed rank test (SPSS) for analysis of differences between paired samples.
Western blots
Western blots for three RELAPSE and three REL_FREE patient cells used in the cell proliferation assay and incubated with kinase inhibitors at 37 °C for 15 minutes were performed as described in supplemental Methods.
Results
The protein abundances of rRNA processing proteins and V-ATPase subunits differ between RELAPSE and REL_FREE patients
We Hierarchical clustering of the 351 differential proteins grouped the patients into two main clusters (Figure 2A) , which corresponded to the RELAPSE and REL_FREE samples, although a distinct separation was not obtained. GO enrichment analysis showed that ATPase activity (coupled to transmembrane movement of ions, rotational mechanism), proton-exporting ATPase activity, phagosome acidification and iron ion transport ( Figure 2B ) were more abundant processes in the To identify protein kinases differentially activated in the two groups we performed phosphorylation site motif analysis (IceLogo). 53 We found a strong bias towards acidic amino acids such as glutamic acid (E) in close proximity to the differentially phosphorylated sites in the RELAPSE group when compared to the unregulated phosphosites (supplemental Figure 5A ), suggesting a higher CSK2 activity in this group. Using differentially phosphorylated sites in the REL_FREE group, the analysis identified a basophilic KXpS/pT motif, suggesting a moderate activation of PRKCA and PRKCD (supplemental Figure 5B) . Several PPI networks of significant cohesiveness were found after ClusterONE analysis based on STRING interactions of differentially phosphorylated proteins ( Figure 3E) . The most significant network (cluster 1) consisted of ten phosphoproteins with higher phosphorylation in RELAPSE patients, most of them being RNA binding proteins. A sequence logo analysis 56 of the amino acids surrounding the 15 phosphosites (corresponding to the ten proteins) suggested a higher activation of CSK2 in this cluster (supplemental Figure 6A ). Other significant clusters included DNA binding proteins (cluster 2 and 4) and proteins involved in nucleic acid metabolism (cluster 3 and 5). A sequence logo analysis of the amino acids surrounding the phosphosites in clusters 2, 3 and 5 showed an enrichment of MAPK substrates (supplemental Figure 6B -D), although NPM1 S125 in cluster 5 is phosphorylated by CSK2 57 , and amino acid sequences around HMGN1, LIG1
and LIG3 phosphosites in cluster 4 suggested the involvement of other kinases such as CSK2 and CDK 58, 59 . Finally, transcription factor BCL11A, which functions as a myeloid proto-oncogene, and DNA repair protein TP53BP1 showed higher phosphorylation on multiple sites in the RELAPSE group relative to the REL_FREE group.
Conversely, PPI networks that showed higher phosphorylation in the REL_FREE group were involved in neutrophil degranulation (cluster 6), membrane organization (cluster 7) and intracellular transport (cluster 8). Sequence logo analysis of the phosphosite motifs in these clusters suggested a higher activation of PRKCD/A kinases (supplemental Figure 6E -G).
To further elucidate the molecular source of AML relapse in these patients, we utilized the proteome and phosphoproteome data in order to determine transcription factors responsible for driving relapse. Specifically, proteins involved in DNA transcription that were regulated at both the proteome or phosphoproteome level in the RELAPSE group were compared to ChIP-seq data from the K562 cell line (stored in the ENCODE database) in order to find potential binding sites of transcription factors (supplemental Table 3 ). We identified six transcription factors (AFF1, CEBPZ, ETV6, IKZF1, PML and TRIM28) that showed predicted regulation of proteins involved in DNA and RNA binding proteins, damaged DNA binding proteins, ribosome and carcinogenesis pathways based on GO molecular function terms and KEGG pathways analysis (supplemental Figure 7) .
To explain the generally increased phosphosite regulation in the RELAPSE group, we compared the protein expression to the 274 differentially regulated phosphosites (corresponding to 169 phosphoproteins). We found that 107 (63%) phosphoproteins were not significantly changed at the protein level (supplemental File 3). Among them, we noticed all the phosphoproteins of the DNA repair network (cluster 2) in Figure 3E (supplemental Figure 8) . In contrast, we spotted 34
proteins significantly regulated at both protein and phosphosite level, including 6 phosphoproteins of the RNA processing network (cluster 1) in Figure 3E (supplemental Table 4 and supplemental Figure 9 ). For majority of these phosphosites (including FLT3 and PML), the phosphorylation levels correlated closely with their protein expression levels. Taking together, while RELAPSE AML cells had higher expression of several phosphorylation-prone proteins, nearly 50% of the differentially regulated phosphorylation sites could not be explained by protein expression changes, suggesting increased kinase-specific phosphorylation.
V-ATPase, CSK2, CDK2/7/9 and CDK4/6 inhibitors affect the proliferation of AML cells
To explore the potential of V-ATPase inhibition in AML, we tested the effect of the V-ATPase inhibitor bafilomycin A1 (BafA1) on the growth of AML cells from four REL_FREE and seven RELAPSE patients with high or low abundance of V-ATPase subunits, respectively (supplemental Figure 10A -C). The proliferation was significantly higher in the untreated control RELAPSE cells compared to REL_FREE cells (supplemental Figure 10D ). BafA1 at 10 nM decreased significantly (P = .018) the proliferation of RELAPSE cells, whereas the proliferation of the REL_FREE cells was not significantly altered (Figure 4A) .
In order to further investigate whether the activity of the predicted RELAPSE-activated kinases was essential for cell viability, we tested proliferation in AML cells from ten RELAPSE and nine REL_FREE patients in the presence of inhibitors of CSK2, CDK2/7/9, CDK4/6 and ERK1/2, alone or in combination (supplemental Figure 11A ). As shown in Figure 4B , the CSK2 inhibitor CX-4945 at 5000 nM was a slightly more potent inhibitor of REL_FREE cells compared to RELAPSE cells. Similarly, the combination of CDK4/6 inhibitor abemaciclib (50 nM) with CDK2/7/9 and CSK2 inhibitors (SNS-032 50 nM; CX-4945 1500 nM) decreased cell proliferation significantly only for the REL_FREE cells (P = .008). The RELAPSE cells showed significant anti-proliferative effect only when exposed to a high concentration (15000 nM) of CX-4945.
Western blot analyses using lysates obtained from AML cells from three RELAPSE and three REL_FREE patients incubated with CDK2/7/9 or ERK1/2 inhibitors showed both higher CDK2 expression and higher phosphorylation of CDK2 on T160 in the RELAPSE group. The phosphorylation of ERK 1/2 was low and similar in the two patient groups (supplemental Figure   11B ). These findings correlate with the phosphoproteome analyses showing higher relative abundance of phosphorylated CDK2 substrates, but not of ERK1/2 substrates, in the RELAPSE group.
Discussion
Despite the patient heterogeneity, significant overall differences were observed at the proteome and phosphoproteome level for several biological processes between AML cells from RELAPSE and REL_FREE patients, harvested at the time of diagnosis. In particular, proteins involved in ribosome biogenesis and rRNA processing/regulation were more abundant and more strongly phosphorylated in RELAPSE patient cells. This finding was supported by the ChIP-seq data analysis from the K562 cell line where we found several transcriptions factors promoting transcription of genes for RNA polymerase (CEBPZ) and ribosome/ribosomal biogenesis (PML, AFF1, ETV6 and TRIM28). Deregulated RNA binding proteins and ribosome biogenesis can be drivers of cancer pathogenesis. 60, 61 Furthermore, the GSEA analysis revealed enrichment of MYC targets in RELAPSE patients. MYC is frequently overexpressed in AML as well as other leukemic malignancies, and seems to be a crucial transcriptional factor during hematopoiesis. 62, 63 MYC is also a regulator of ribosome biogenesis 64 , activates RNA pol I for rDNA transcription 65 and induces snoRNA expression 66 . As MYC targets are enriched during relapse, our findings suggest that MYC, together with proteins involved in rRNA processing and ribosome biogenesis, are prognostic biomarkers for relapse and potential therapeutic targets in AML. Several drugs targeting rRNA synthesis, transcription or processing in hematological cancers have already been described. 67, 68 We observed decreased abundance of V-ATPase subunits in RELAPSE patients. The V-ATPase complex can modulate several intracellular signaling pathways with importance in AML (such as PI3K-mTOR 69, 70 , NOTCH1 71 and WNT 72 ) by controlling acidification of intracellular compartments. When testing the effect of V-ATPase inhibitor on AML cells we observed that the
RELAPSE derived cells with initially low abundance of V-ATPase subunits responded better to
BafA1 V-ATPase inhibitor, thus, a potential relationship between low initial V-ATPase subunit abundance and chemoresistance needs further evaluation. V-ATPase is regarded as a potential therapeutic target in AML. 73 Although material from only a limited number of patients was available for testing in the proliferation assay, differences in proteomic profiles were associated with differences in anti-proliferative pharmacological effects.
Alignment of sequences surrounding phosphorylation sites and KSEA analysis of our full phosphoproteomics dataset showed an enrichment of phosphorylated substrate groups of MAPK, CSK2, CDK, PAK, PRKC and AKT kinases. We additionally observed that RELAPSE cells had higher activity of CDK2 and higher expression based on immunoblotting assays compared to REL_FREE cells. As similarly demonstrated previously, KSEA of phosphoproteome data of AML-derived cells from 20 patients had similar enrichment of CSK2, CDK, PAK, AKT, ABL, SRC, MAPK, PRKA and PRKC kinases relative to normal peripheral blood stem CD34 + cells from 5 healthy donors. 55 Thus, two independent phosphoproteomics studies on different AML patient cohorts have identified similar sets of kinase upregulations in AML.
The CSK2 inhibitor CX-4945 had a stronger anti-proliferative effect for REL_FREE cells than for RELAPSE cells when acting alone or in combination with CDK inhibitors. Further studies are required to determine whether RELAPSE cells owe their higher CSK2 inhibitor resistance to generally increased robustness or to lower turnover of CSK2-mediated phosphorylation.
Comprehensive KSEA, sequence logos and antibody blotting analyses show that CSK2 and
CDKs could be suggested as strong RELAPSE promoters. CSK2 in particular is a key regulator of several signaling networks and is overexpressed in many hematological cancers. 74 The activity of CDK2 (and potentially also CDK4, CDK6, CDK7 and CDK9) in RELAPSE patients may further increase AML cell proliferation by triggering G1-S-phase transitions. 75 Several phosphoproteins were multi-phosphorylated, like BCL11A with several phosphosites upregulated in the RELAPSE group (S205, T208, S608, S625, S630 and S718). BCL11A, a transcription factor associated with the BAF SWI/SNF chromatin remodeling complex, may play a role in leukemogenesis 76 and its expression is associated with adverse outcome in AML. 77 In a previous phosphoproteomics study with AML patients treated with the FLT3 inhibitor quizartinib, increased phosphorylation of BCL11A S630 was associated with nonresponsiveness. 24 Taken together these results suggest that BCL11A phosphorylation contributes to chemoresistance in AML. TP53BP1, another multi-phosphorylated protein in RELAPSE patients, is a double-strand DNA break repair protein that is phosphorylated at multiple sites in response to DNA damage. Moreover, phosphorylation at S1219 by ATM kinase seems to be a response to ionizing radiation. 78 The S523Q motif might also serve as substrate for ATM kinase and being part of the RIF1, a non-homologous end joining-mediated repair protein, recruitment process to DNA break sites. 79 The stimulatory T190 and T191 phosphosites in the activation loop of NEK7 showed increased phosphorylation in the REL_FREE patients. NEK7 seems to be involved in the recruitment of centrosomal pericentriolar proteins that are necessary for centriole duplication and spindle pole formation during mitosis. 80 Chromosomal lagging, micronuclei formation, cytokinesis failure and tetraploidy/aneuploidy were observed in NEK7 deficient mouse embryonic fibroblasts. 81 Therefore, deregulation of NEK7 activity in cell division processes might contribute to aberrant mitosis and induction of the relapse status. 82 Furthermore, we found two phosphosites, S372 and S389 in the ribosomal S6 kinase RPS6KA1 isoform 2 (Uniprot identifier: Q15418-2) upregulated in REL_FREE patients. It has been reported that phosphorylation at S372 and S389, possibly by PRKC activators, switched on the RPS6KA1 N-terminal kinase domain required for phosphorylation of its substrates. 83 The role of ribosomal S6 kinases in cancer is not well understood and seems to vary by cancer type. While some isoforms of ribosomal S6 kinases can promote cell motility and invasion processes by altering transcription and integrin activity, others depress them by interacting with the actin cytoskeleton. 84 The fact that the phosphosites of FC of phosphorylation are color-coded; purple-colored proteins showed a higher phosphorylation in the RELAPSE group and green-colored proteins showed a higher phosphorylation in the REL_FREE group. Kinases are specifically distinguished using hexagon shapes. DNA excision repair P value 3.00E-2
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